BioLife Solutions, Inc.
BLFS scores 53.7 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Moderate penalties (-5.2 points) reflect identified risk factors. The overall score balances these against the stock's fundamental strengths.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| BLFS | 53.7 | N/A | -42.6% | -4.3% | $1.1B |
| INCY | 89.6 | 15.8 | 21.2% | 25.0% | $19.6B |
| GMAB | 85.6 | 13.1 | 22.8% | 36.4% | $17.9B |
| CPRX | 82.1 | 13.7 | 23.5% | 37.6% | $3.0B |
| VRTX | 78.0 | 32.1 | 8.9% | 32.9% | $121.8B |
| ASND | 75.8 | 16.6 | 98.0% | -31.7% | $13.8B |
| NBIX | 74.8 | 26.5 | 21.4% | 16.7% | $13.1B |
| AMGN | 73.9 | 26.0 | 10.0% | 21.0% | $204.8B |
| ARGX | 73.5 | 35.1 | 78.6% | 38.0% | $47.4B |
| HOLX | 73.3 | 31.1 | 1.7% | 13.8% | $16.8B |
| REGN | 72.4 | 19.4 | 1.0% | 31.4% | $80.2B |
| ISRG | 72.2 | 61.7 | 20.5% | 28.4% | $180.9B |
| EXEL | 71.6 | 15.1 | 7.0% | 33.7% | $11.9B |
| ALKS | 71.5 | 16.5 | -6.4% | 23.9% | $5.0B |
| KRYS | 71.0 | 41.4 | 473.0% | 30.7% | $7.9B |
| HALO | 70.3 | 16.8 | 22.4% | 43.7% | $8.2B |
| Sector Average | 37.0 | 41.9 | 161.5% | -3292.7% | — |
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Stock is building a base after a decline. The 200-day moving average is flattening. Watch for a breakout above the 200-day SMA on increased volume.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $28M | $25M | $24M | $-3M |
| Gross Profit | $17M | $16M | $16M | $8M |
| Operating Income | $-89,000 | $-17M | $-1M | $1M |
| Net Income | $621,000 | $-16M | $-448,000 | $12M |
| EPS (Diluted) | $0.01 | $-0.33 | $-0.01 | $0.26 |
| Gross Margin | 61.4% | 64.6% | 65.9% | N/A |
| Operating Margin | -0.3% | -65.5% | -5.1% | N/A |
| Net Margin | 2.2% | -62.3% | -1.9% | N/A |
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $28.15 | $60.67 | 73.2% | Wide |
| 2022 | $10.40 | $38.01 | 114.1% | Wide |
| 2023 | $8.92 | $26.89 | 100.4% | Wide |
| 2024 | $14.50 | $28.88 | 66.3% | Wide |
| 2025 | $19.10 | $29.62 | 43.2% | Wide |
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.